| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 The future of infection imaging Buscombe JRQ J Nucl Med Mol Imaging  2006[Jun]; 50 (2): 99-103Over the past 10 years, there has been an unprecedented explosion in new agents  suggested for imaging infection. These agents have been based on our  understanding of the processes involved in invasive infection of the body by  microorganisms and the body's response to them. Work with antibodies has  traditionally yielded the most likely candidates, 3 of which have entered  clinical use in Europe and the USA. However, the expense and limitations of  producing antibodies have resulted in investigations into the use of cytokine and  anti-microbial radiolabelled peptides. This work is very promising in that these  types of tracers may be more specific for infection than labelled leukocytes.  There remains a big question mark, however, as to whether or not these will  progress from phase I/II trials to phase III trials and, ultimately, to clinical  use. Finally, the investigation of radiolabelled anti-microbials continues and  may prove to be most useful with anti-fungals especially in the immuno-suppressed  host. We live in exciting times in the evolution of infection imaging; time and  commercial constraints will determine which, if any of these tracers make it to  the market and will they do so before PET rules all nuclear medicine?|*Antibodies, Monoclonal[MESH]|*Antimicrobial Cationic Peptides[MESH]|*Cytokines[MESH]|*Radioisotopes[MESH]|Forecasting[MESH]|Humans[MESH]|Infections/*diagnostic imaging[MESH]|Nuclear Medicine/*trends[MESH]|Positron-Emission Tomography/*trends[MESH]|Radiopharmaceuticals[MESH]
 |